VBWG - Resource Item

Resources

Quick Order
About Create Profile Login
Email: Password:

Slide Lecture Programs
2000 Core Curriculum cash advance cash advance
The endothelium: New insights into the origins and treatment of CAD cash advance cash advance
August 31, 2000
Table of Contents - 119 slides
No.	Title
1	The endothelium: New insights into the origins and treatment of CAD cash advance cash advance
2	Program overview cash advance cash advance
3	The endothelium maintains vascular health cash advance cash advance
4	Unifying model: Endothelial dysfunction to CVD cash advance cash advance
5	Physiology of NO in the human coronary and peripheral vasculature cash advance cash advance
6	Physiology of NO in the human coronary and peripheral vasculature: Mechanisms of NO release cash advance cash advance
7	Atherosclerosis timeline cash advance cash advance
8	Therapeutic strategies for the treatment of endothelial function cash advance cash advance
9	Candidates for therapies to enhance endothelial function cash advance cash advance
10	Brachial FMD predicts coronary endothelial function cash advance cash advance
11	Exercise improves coronary endothelial function in CAD cash advance cash advance
12	Vitamin E and endothelial function in smokers cash advance cash advance
13	Oral omega-3 fatty acids improve endothelial function in hypercholesterolemia cash advance cash advance
14	Estrogen and vitamin E effects in postmenopausal women cash advance cash advance
15	Tissue ACE inhibition and endothelial function cash advance cash advance
16	Tetrahydrobiopterin supplementation restores endothelial function in smokers cash advance cash advance
17	Effects of antihypertensive agents on endothelial function in postmenopausal women cash advance cash advance
18	Spironolactone improves endothelial function in CHF cash advance cash advance
19	Improving endothelial function: Most compelling data cash advance cash advance
20	Components and major actions of the renin angiotensin system cash advance cash advance
21	Vasculoprotective effects of angiotensin-(1-7) cash advance cash advance
22	ACE metabolizes Ang-(1-7) into Ang-(1-5): Effect with and without ACE inhibition cash advance cash advance
23	ACE and endothelial function cash advance cash advance
24	Mechanisms for the effects of ACE inhibition on endothelial dysfunction cash advance cash advance
25	Potential benefits of suppressing cardiac ACE cash advance cash advance
26	Mechanisms of cardiac RAS activation in cardiac remodeling cash advance cash advance
27	Possible mechanisms of endothelial dysfunction in heart failure cash advance cash advance
28	Effect of experimental heart failure on cardiac ACE activity cash advance cash advance
29	Genetic evidence that cardiac ACE correlates with experimental infarct size cash advance cash advance
30	Neointima formation: Correlation with blood pressure and residual serum and tissue ACE after ACE-I cash advance cash advance
31	ACE inhibitors and fibrinolysis cash advance cash advance
32	Vasculoprotective effects of tissue ACE inhibition cash advance cash advance
33	Cardiovascular role of bradykinin as determined by knockout mice cash advance cash advance
34	ACE inhibition increases vasodilation by a bradykinin mechanism in response to flow-mediated dilation cash advance cash advance
35	Effects of ACE-I vs other antihypertensive agents on endothelial function in hypertensive patients cash advance cash advance
36	ACE inhibitors and endothelial function: Evidence for the role of NO and bradykinin cash advance cash advance
37	ACE inhibitors upregulate b-adrenergic receptors on cardiac myocytes by a bradykinin mechanism cash advance cash advance
38	Correlation between endothelial function and hypertension cash advance cash advance
39	Correlation between endothelial function and atherosclerosis cash advance cash advance
40	Severe endothelial dysfunction associated with increased CV risk in patients with mild CAD cash advance cash advance
41	Endothelial dysfunction predicts cardiovascular events: 5-year follow-up in patients with angina cash advance cash advance
42	Endothelial function vs clinical outcome in patients with CAD cash advance cash advance
43	Carotid plaque is a marker of CV risk cash advance cash advance
44	Carotid atherosclerosis and systolic blood pressure cash advance cash advance
45	New treatment approach to hypertension cash advance cash advance
46	JNC-VI guidelines: Risk stratification and treatment cash advance cash advance
47	JNC-VI guidelines: Compelling indications cash advance cash advance
48	Vascular changes and CV risk factors in borderline hypertension (BP > 140/90 mm Hg) cash advance cash advance
49	Reduction in systolic blood pressure with quinapril by patient age cash advance cash advance
50	Efficacy of quinapril vs captopril in moderate-to-severe hypertension cash advance cash advance
51	Combined and distinct vascular effects of ACE-I and statins: Effect on blood pressure cash advance cash advance
52	Combined and distinct vascular effects of ACE-I and statins: Effect on hemodynamic reactivity cash advance cash advance
53	Blood pressure control after 8 weeks of quinapril: Effect of age and gender cash advance cash advance
54	Blood pressure control after 8 weeks of quinapril: Effect of race cash advance cash advance
55	ACE inhibitor therapy: Effect on vascular and cardiac structure in hypertensive patients cash advance cash advance
56	Quinapril reduces blood pressure and vascular hypertrophy cash advance cash advance
57	Effect of quinapril on ST-segment depression in patients with angina cash advance cash advance
58	Quinapril improves fasting glucose levels in type 2 diabetes cash advance cash advance
59	Quinapril + HCTZ fixed combinations trials: Design cash advance cash advance
60	Quinapril 10 mg/HCTZ 12.5 mg study: Results cash advance cash advance
61	Quinapril 20 mg/HCTZ 12.5 mg study: Efficacy cash advance cash advance
62	UKPDS: Importance of tight control of both BP and glycemia on risk of diabetes complications cash advance cash advance
63	Change in vascular ACE density after arterial injury and effect of quinapril to prevent restenosis cash advance cash advance
64	Quinaprilat improves blood flow in ischemic myocardium cash advance cash advance
65	Quinaprilat reduces total coronary resistance: Ischemic regions cash advance cash advance
66	Quinaprilat reduces total coronary resistance: Non-ischemic regions cash advance cash advance
67	ATIME: Slower dose escalation of quinapril improves blood pressure control cash advance cash advance
68	Hypercholesterolemia induces AT₁ receptor expression cash advance cash advance
69	Relative risks for heart failure: Framingham Study cash advance cash advance
70	Progression of hypertension to LVH and heart failure cash advance cash advance
71	Effect of ACE inhibition on mortality and morbidity in heart failure patients: An analysis of 32 trials cash advance cash advance
72	LVH regression: Changes in left ventricular mass index with 4 drug classes cash advance cash advance
73	LVH is normalized in most patients with long-term quinapril treatment cash advance cash advance
74	Effect of ACE inhibition on FMD in patients with heart failure cash advance cash advance
75	Increasing dosages of enalaprilat did not affect FMD cash advance cash advance
76	Effect of quinapril on b-receptor function in heart failure cash advance cash advance
77	Effect of quinapril on b-receptor density cash advance cash advance
78	ATLAS: High- vs low-dose ACE inhibition in heart failure?study design cash advance cash advance
79	ATLAS: High-dose ACE-I reduces adverse outcomes in heart failure cash advance cash advance
80	ACE inhibitors in CHF: Are maximally recommended doses sufficient? cash advance cash advance
81	Comparative inhibition of plasma and tissue ACE cash advance cash advance
82	Relative potency of ACE inhibitors in plasma and tissue cash advance cash advance
83	Relative potency of ACE inhibitors in human heart and lung cash advance cash advance
84	Comparative dissociation rates of ACE inhibitors from human atrial membranes cash advance cash advance
85	ACE inhibition: Pharmacokinetic overview cash advance cash advance
86	Differential effects of quinapril and losartan on superoxide production in endothelial cells cash advance cash advance
87	ACE inhibitors and ARBs: Comparative effects on postprandial endothelial function cash advance cash advance
88	Comparative effect of ACE inhibition and AR blockade on fibrinolytic balance cash advance cash advance
89	Quinapril but not losartan improves survival in cardiomyopathic hamsters cash advance cash advance
90	ACE inhibitors vs ARBs in heart failure trials: Study characteristics cash advance cash advance
91	RESOLVD: Clinical results cash advance cash advance
92	ELITE II: Study design cash advance cash advance
93	ELITE II: Study results cash advance cash advance
94	ACE inhibitors vs ARBs in heart failure: Effects on mortality and hospitalization cash advance cash advance
95	ELITE I substudy compares the effects of ACE inhibition and AR blockade on LV remodeling cash advance cash advance
96	ACE inhibitors vs ARBs in heart failure: Clinical summary cash advance cash advance
97	Tissue ACE trials in patients with CAD and preserved LV function cash advance cash advance
98	TREND: Endothelial function and ACE inhibition cash advance cash advance
99	TREND: Influence of smoking status on progression of endothelial dysfunction cash advance cash advance
100	TREND: Effect of smoking and ACE-I on coronary artery segment diameter cash advance cash advance
101	BANFF: Effect of ACE inhibitors vs other cardiovascular agents on FMD cash advance cash advance
102	BANFF: Results by ACE genotype cash advance cash advance
103	Trials of ACE inhibition effects on outcomes following revascularization cash advance cash advance
104	APRES: Effect of ramipril on cardiac outcomes cash advance cash advance
105	QUO VADIS: Effects of quinapril on ischemia cash advance cash advance
106	QUO VADIS: Chronic ACE inhibition and Ang II formation in internal mammary artery segments cash advance cash advance
107	New tissue ACE trials: Differences in scope cash advance cash advance
108	QUIET: Design and methods cash advance cash advance
109	QUIET: Cardiac death, nonfatal MI, or VT/VF cash advance cash advance
110	QUIET: Effect of quinapril on CAD progression according to LDL-C level cash advance cash advance
111	HOPE: Design and methods cash advance cash advance
112	HOPE: Primary outcome (MI, stroke, CV death) cash advance cash advance
113	HOPE: Risk reduction with ACE inhibition cash advance cash advance
114	HOPE: Risk reduction in diabetic cohort cash advance cash advance
115	HOPE: Baseline SBP vs global endpoint cash advance cash advance
116	Tissue ACE trials in patients with CAD and preserved LV function: Benefits observed cash advance cash advance
117	Tissue ACE trials in patients with CAD and preserved LV function: Implications for clinical practice cash advance cash advance
118	EUROPA: An upcoming tissue ACE trial cash advance cash advance
119	EUROPA substudies: Confirmation of pathophysiologic concepts cash advance cash advance


Home \| Literature Update \| Journal Link \| Resources \| Meeting Highlights \| Members \| About VBWG \| Web Links